Pain - Identifying and Commercializing First-in-Class Innovation; New Report Launched

Big Pharma Drives Innovation in Pain Therapy Development, Despite Declining Patent Applications

Patent applications for novel pain therapeutics declined steadily in number from 4,970 in 2008 to 3,492 in 2012, an average annual decrease of 8%, as limited understanding of pain pathophysiology continues to hinder drug development in this arena, according to new report.

The company’s latest report states that patent applications for pain treatments between 2008 and 2012 were dominated by Big Pharma, including Sanofi, Novartis and Merck & Co. (Merck), which submitted 169, 162 and 142 applications, respectively.

However, according to Publisher, the global pain treatment market is dominated by opioids and steroidal anti-inflammatory drugs, with no novel products currently able to challenge these products’ efficacy in treating moderate to severe acute pain.

Furthermore, despite the significant unmet needs for more effective therapies in other pain subtypes, such as chronic and neuropathic pain, due to their rising prevalence, the factors underpinning these subtypes are complex and poorly understood.

However, this limited knowledge is being countered by technological advances and significant research efforts, with new insights translating into an expanding pool of novel therapeutic targets.

Publisher states that the overall pain therapy pipeline is exceptionally large and moderately diverse, with a number of molecules boasting different mechanisms of action to those seen in the current market landscape. This offers a high probability of producing strong market entrants in the near future.

Indeed, among the 111 first-in-class pipeline products available for strategic consolidations, some have shown promising Preclinical evidence and significant potential to become game-changing treatments, representing high-reward investments.

Publisher believes that such innovation in the pain therapeutics field is being driven primarily by Big Pharma, due to the large number of patent grants awarded to these companies for their treatments between 2008 and 2012.

Merck boasted the highest number of patent grants during this period, with 59, while Boehringer Ingelheim and Allergan achieved 35 and 34, respectively, and Sanofi and Novartis both achieved 30.

Frontier Pharma: Pain - Identifying and Commercializing First-in-Class Innovation report provides a comprehensive review of the pipeline for first-in-class pain therapies, analyzed on the basis of stage of development, molecule type and molecular target. The report also assesses the licensing and co-development deal landscape for pain therapies and the benchmarking of deals involving first-in-class versus non-first-in-class products.

For further information on this report, please visit- http://mrr.cm/4x7

Find all Diseases Reports at: http://www.marketresearchreports.com/diseases